Literature DB >> 1385821

Effects of repeated botulinum toxin injections on orbicularis oculi muscle.

G E Borodic1, R Ferrante.   

Abstract

Histologic evaluation was conducted on 12 orbicularis oculi specimens from 11 patients with essential blepharospasm and Meige's disease who had received an average of 11.3 injections of botulinum A toxin over 3.5 years. Denervation was demonstrated by the spread of acetylcholinesterase staining on muscle fibers when specimens were evaluated within 11 weeks of the last injection. When specimens were taken after 12 weeks, spread of acetylcholinesterase was confined to the neuromuscular junctions, with little fiber size variability resembling normal muscle. Fibrosis seen in three specimens could be correlated to prior surgery. Repeated injections of botulinum toxin into human muscle do not appear to cause irreversible muscle atrophy or other degenerative changes. Denervation changes (fiber size variability, acetylcholinesterase spread) appear to correlate to the time interval since the last injection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385821     DOI: 10.3109/01658109209058127

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  16 in total

1.  Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study.

Authors:  C Butera; R Guerriero; S Amadio; D Ungaro; H Tesfaghebriel; F Bianchi; G Comi; U Del Carro
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

2.  Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.

Authors:  A R Bentivoglio; A Fasano; T Ialongo; F Soleti; S Lo Fermo; A Albanese
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

3.  Is active sweating during heat acclimation required for improvements in peripheral sweat gland function?

Authors:  Michael J Buono; Travis R Numan; Ryan M Claros; Stephanie K Brodine; Fred W Kolkhorst
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-08-05       Impact factor: 3.619

Review 4.  New concepts in botulinum toxin therapy.

Authors:  G E Borodic; L B Pearce
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

5.  Dramatic changes in muscle contractile and structural properties after 2 botulinum toxin injections.

Authors:  Viviane B Minamoto; Kentaro P Suzuki; Shannon N Bremner; Richard L Lieber; Samuel R Ward
Journal:  Muscle Nerve       Date:  2015-06-30       Impact factor: 3.217

6.  Quantifying muscle asymmetries in cervical dystonia with electrical impedance: a preliminary assessment.

Authors:  Codrin Lungu; Andrew W Tarulli; Daniel Tarsy; Phillip Mongiovi; Veronique G Vanderhorst; Seward B Rutkove
Journal:  Clin Neurophysiol       Date:  2010-10-12       Impact factor: 3.708

7.  A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.

Authors:  Kenneth Ka Hei Lai; Alan Tsang; Andrew K T Kuk; Callie K L Ko; Edwin Chan; Simon T C Ko
Journal:  Neuroophthalmology       Date:  2021-05-19

8.  Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.

Authors:  Ibrahim Fathi Ghalayini; Mohammed A Al-Ghazo; Ziad Ali Elnasser
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

Review 9.  Drug Insight: biological effects of botulinum toxin A in the lower urinary tract.

Authors:  Michael B Chancellor; Clare J Fowler; Apostolos Apostolidis; William C de Groat; Christopher P Smith; George T Somogyi; K Roger Aoki
Journal:  Nat Clin Pract Urol       Date:  2008-05-06

Review 10.  Contribution of Single-Fiber Evaluation on Monitoring Outcomes Following Injection of Botulinum Toxin-A: A Narrative Review of the Literature.

Authors:  Hélène Moron; Corine Gagnard-Landra; David Guiraud; Arnaud Dupeyron
Journal:  Toxins (Basel)       Date:  2021-05-17       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.